¹Department of Medicine & Emergency Medicine ,Veterans Administration Medical Center, Teaching Hospital, Warren Alpert Medical School of Brown University, Providence, Rhode Island 02908 USA; ²Department of Emergency Medicine Roger Williams Medical Center Providence, Rhode Island 02908 USA
*Corresponding author: Ricky W. McCullough MD, MSc at Mueller Medical International Translational Medicine Research Center 1768 Storrs Road, Storrs-Mansfield CT 06268; Department of Medicine and Emergency Medicine Providence Veterans Administration Hospital, Brown University Teaching Hospital, 830 Chalkstone Avenue, Providence RI. E-mail: firstname.lastname@example.org , Phone: 860-477-0961
Published: December 23, 2014.
The quest to optimize cancer treatments and to extend cancer survival is consistently thwarted by an unavoidable but expected consequence – mucositis of the oral and gastrointestinal tract. Prior to market approval our Translational Medicine Research Center clinically tested polymerized cross-linked sucralfate (PCLS) on a cancer treatment patient who underwent 6 weeks chemo-radiation for squamous cell carcinoma of head and neck (SCCHN).This late-breaking Phase 4 observational experience from our Center discusses the post-approval use of PCLS (ProThelial™) in 2 patients: one with advanced oroesophageal mucositis from radiation and cetuximab for SCCHN and another patient with oral, esophageal, small and large bowel mucositis caused by Folfirinox (5- fluorouracil, folinic acid, irinotecan and oxaliplatin) for inoperable metastatic pancreatic adenocarcinoma.Standard potency sucralfate is not recommended in the mucositis management guidelines of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC\ISOO). This higher potency sucralfate, PCLS, used in these patients exhibited an unprecedented simultaneously and rapid (2-3 day) reversal of oroesophageal mucositis and alimentary mucositis. These results raise the novel proposition of single-agent management of both oral and alimentary mucositis caused by radiation, classic and newer bioengineered oncolytics. If validated, PCLS should energize discussions regarding mucositis clinical guidelines.The experience of these patients has been accepted for presentation in the upcoming 2014 International Symposium of the MASCC\ISOO. Distinctions between standard potency sucralfate and PCLS are reviewed and modes of action explanations are offered.
- Stiff PJ. Emesis and Mucositis. Managing oral mucositis in patients with hematologic malignancies. J Support Oncol 2006; 4(2):79 published at www.oncologypractice.com/jso/ journal/ articles/0402079.pdf [www.SupportiveOncology.net ]
- Brown CG, Wingard J. Clinical consequences of oral mucositis. Seminars in Oncology Nursing 2004; 20:16-21.
- Mayer DK, Travers D, Wyss A, Leak A, Waller A. Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncology 2011; 29(19): 2683-2688.
- Uramoto H, Iwashige A, Kagami S, Tsukada J. Prediction of emergency hospitalization of outpatients receiving cancer chemotherapy. Anticancer Res 2007; 27(2):1133-6.
- Barbera L, Taylor C, Dudgeon D. Why do patients with cancer visit the emergency department near the end of life? CMAJ 2010; 182(6): 5638.
- Elting LS, Cooksley CD, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98(7): 1531-9.
- Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001; 19(8):2201-5.
- FDA http://www.accessdata.fda.gov/drugsatfdadocs/label/2004/ 125103lbl.pdf
- Rose-Ped AM, Bellm LA, Epstein JB, Trotti A. Gweded C, Fuchs HJ. Comlications of radiation therapy for head and neck cancers. The patient’s perspective. Cancer Nursing 2002; 25:461-467.
- McCullough RW. High-potency sucralfate prevents and rapidly reverses chemo-radiation mucositis in a patient with stage 4b head and neck cancer. World J Transl Med 2013; 2(2):13-21.
- Kashimura K, Ozawa K. Sucralfate Preparations. US Patent 5,968,906. Oct 19, 1999.
- Mian Mashhud Ahmad MD et al (2004) High potency sucralfate treatment of Erosive GERD, NERD & Co-morbid IBS, a randomized, double blinded placebo-controlled trial. Clinical trial data on file at Mueller Medical. Abstract accepted for presentation at DDW 2014 of American Gastroenterological Association.
- Mian Mashhud Ahmad MD et al (2005) Accelerated mucosal healing using high potency sucralfate. A seven day randomized comparison to omeprazole, ranitidine and antacids in erosive GERD. Clinical trial data on file at Mueller Medical. Abstract accepted for presentation at DDW 2014 of American Gastroenterological Association.
- InClone LLC 2004-2013. Erbitux (Cetuximab) wholly-owned subsidiary of Eli Lilly and Bristol-Myers Squibb Company. Rev August 2013 Package insert.
- Glasziou P, Chalmers I, Rawlins M, McCullouch P. When are randomized trials unnecessary? Picking signal from noise. BMJ Feb (2007) 334:349-351.
- Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FKL, Barasch A, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008; 113(10):2704-13.
- Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients with cancer. Dent Clin North Am 2008; 52(1):61-77,viii.
- Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004; 100(9 Suppl): 2026-46.
- Tarnawski A, Hollander D, Krause WJ, Zipser RD, Stachura J, Gergely H. Does sucralfate affect the normal gastric mucosa? Histologic, ultrastructural, and functional assessment in the rat. Gastroenterology 1986; 90:893-905.
- Danesh JZ, Duncan A, Russell RI, Mitchell G. Effect of intragastric pH on mucosal protective action on sucralfate. Gut 1988; 29(10):1379-85.
- Tarnawski A, Hollander D, Stachura J, Mach T, Bogdal J. Effect of sucralfate on the normal human gastric mucosa. Endoscopic, histologic, and ultrastructural assessment. Scand J Gastroenterolol Suppl 1987; 127:111-23.
- Hollander D, Tarnawski A, Krause WJ, Gergely H. Protective effect of sucralfate against alcohol-induced gastric mucosal injury in the rat. Macroscopic, histologic, ultrastructural, and functional time sequence analysis. Gastroenterol 1985; 88(1Pt2):366-74.
- Slomiany BL, Liu J, Yao P, Wu-Wang CY, Keogh JP, Wang SL,et al. Characterization of epidermal growth factor receptor in gastric mucosa. Digestion 1990; 47(4):181-90.
- Tarnawski A, Stachura J, Durbin T, Sarfeh IJ, Gergely H. Increased expression of epidermal growth factor receptor during gastric ulcer healing rats. Gastroenterology 1992; 102(2):695-8.
- Konturek JW, Brzozowski T, Kontureck SJ. Epidermal growth factor in protection, repair and healing of gastroduodenal mucosa. J Clin Gastroenterol 1991; 13(Suppl 1):S88-S97.
- Tarnawski A, Jones K. The role of EGF and its receptor in mucosal protection, adaptation to injury and ulcer healing. Involvement of EGF-R signal transduction pathways. J Clin Gastroenterology 1998; 27:S12-20.
- Nexo E, Poulsen SS. Does epidermal growth factor play a role in the action of sucralfate? Scand J Gastroenterol Suppl 1987; 127:45-9.
- Itoh M, Imai S, Yasue N et al. Combination of EGF and sucralfate significantly accelerates the healing of chronic gastric ulcers in the rat. Gastroenterology 1989; Abstract A229.
- Konturek SJ, Brzozowski T, Bielanski W, Warzecha Z, Drozdowicz D. Epidermal growth factor in the gastroprotective and ulcer-healing actions of sucralfate in rats. Am J Med 1989; 86(Suppl 6a):32-7.
The fully formatted PDF version is available.
Int J Biomed. 2014; 4(4):242-247. © 2014 International Medical Research and Development Corporation. All rights reserved.